Field report E-33 / L6 · sheet /deals

M&A & DealsFiled from the territory

Isomorphic Labs raises $5 billion to push AI drug candidates to trials

Alphabet-backed Isomorphic Labs raised $5 billion to scale its IsoDDE platform, with more than 20 programs underway and plans to begin testing its first drugs before 2026 ends.

Grid
E-33 / L6
Surveyed
November 20, 2026
Reading
3 min read
Correspondent
Priya Raman
Alphabet's Isomorphic Labs raised $5 billion in Series C funding for AI drug design
Fig. E-33 / L6Alphabet's Isomorphic Labs raised $5 billion in Series C funding for AI drug design — elliepeek / pixabay

Field notes

  1. Isomorphic Labs raised $5 billion in a Series C round.
  2. Greenoaks and Sequoia Capital led the financing.
  3. The company has more than 20 programmes under way.
  4. Hassabis aims to start clinical testing of the first drugs before 2026 ends.
  5. Drug-discovery startups raised a record $23.2 billion during 2026.

By Priya Raman

Isomorphic Labs has raised $5 billion in a Series C round to scale its AI drug-design engine and move its first drug candidates toward clinical trials, the Alphabet-backed company said Tuesday. The financing backs a transition from biological modelling to the infrastructure required for clinical development.

Greenoaks and Sequoia Capital led the round jointly. Andreessen Horowitz and several other new investors joined them, while Alphabet continued a significant investment in the unit founded by Sir Demis Hassabis.

Every existing investor took part, the company said:

  • Thrive Capital
  • MGX
  • GV
  • CapitalG
  • Temasek
  • U.K. Sovereign AI Fund

Hassabis set out the intended use of the capital: “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” he said in the company announcement, according to CNBC.

What does the $5 billion fund?

The money has three connected jobs, all tied to moving drug candidates out of research and toward testing:

  • Scale IsoDDE, Isomorphic’s drug-design engine, which combines AI simulation models across multiple therapeutic areas and drug modalities, or distinct treatment formats.
  • Build translational and clinical development infrastructure covering the route from laboratory research toward human testing.
  • Advance the company’s drug candidates toward clinical trials.

Isomorphic also reported positive preclinical results, meaning results obtained before human trials, from internal oncology and immunology programmes and from work with partners. Those results provide the scientific basis for the next stage, but the funding also signals that clinical execution will consume substantially more resources than early-stage research.

How large is the pipeline?

Isomorphic has more than 20 programmes under way, according to Bloomberg, giving the company a portfolio rather than a single lead asset. Hassabis told Bloomberg: “What we're trying to build is a platform to do hundreds of drugs a year.”

The timeline remains less settled than the financing. In January, Hassabis said Isomorphic aimed to begin testing its first drugs in clinical studies before 2026 ended, according to Bloomberg. When interviewed in November, he would not offer a revised timetable.

He did say regulatory filings for the first oncology programme were progressing as planned and that Isomorphic would have further news to announce in 2027. The near-term test for investors is therefore whether the company can complete that regulatory work and start clinical testing on schedule.

What remains unconfirmed?

Isomorphic did not disclose its valuation, according to Bloomberg. An earlier Bloomberg report said the company was preparing a $5 billion raise that would value it at about $50 billion.

The distinction matters: the $5 billion funding amount is confirmed, while the roughly $50 billion valuation was a reported target rather than a disclosed transaction price.

The round follows a $2.1 billion Series B that Isomorphic raised in May, according to CNBC. It also comes as startups focused on finding new drugs pulled in a record $23.2 billion during 2026, placing Isomorphic’s raise within a broader surge in biotechnology funding.

Who leads Isomorphic through the round?

Alphabet announced a leadership reshuffle in August in which Hassabis would step down as CEO of Google DeepMind, become the unit’s chairman and Alphabet’s chief scientist, while continuing to lead Isomorphic. His continuing role keeps him in charge of the company’s model development and clinical push.

The funding now allows Isomorphic to advance its software, development infrastructure and drug pipeline at once. Its next disclosed checkpoints are the start of clinical testing before 2026 ends, continued regulatory work on the first oncology programme and further company news in 2027. The strategic logic is straightforward: capital can accelerate preparation for trials, but it cannot remove the need to deliver those milestones on schedule.

via qz.com (Source)

Share this article:

More from Priya Raman

Priya Raman

Show full bio

Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.

496 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetE-33 / L6 · November 20, 2026